

Market insights summary

European heart valve device market

What's trending?

There is rising adoption of premium-priced transcatheter devices and a growing preference for minimal invasive techniques

- Because physicians and patients prefer less invasive options, there is a growing preference for transcatheter replacement and repair devices.
- With continued innovation in the transcatheter space, new technologies are offering enhanced durability and broader clinical applicability.

Competitors are actively investing in developing transcatheter devices with innovative features to increase their competitiveness in this space

- Edwards Lifesciences led the European heart valve device market in 2024, driven by strong clinical evidence supporting its next-generation transcatheter systems such as the EVOQUE and SAPIEN series (including SAPIEN 3 Ultra, M3, M3 Ultra Resilia, and SAPIEN 3 Transcatheter Pulmonary Valve Implantation (TPVI) with Alterra Adaptive). The company has also invested in strategic acquisitions that continue to expand its market presence.
- Abbott Laboratories ranked second in the European heart valve device market, supported by its strong leadership in the transcatheter repair segment and the expanded indication approval of its Navitor Transcatheter Aortic Valve Implantation (TAVI) system for treating low- to intermediate-risk severe aortic stenosis patients.

Access more insights and data in the [report](#).
[Speak to our team](#) to see how we can power your innovation.

2024 European heart valve device market snapshot


\$2.15B

Market value


4.3%

CAGR ('19-'34)


European heart valve device market by country




European heart valve device market by product type



2024 European heart valve device competitive landscape



Transcatheter heart valve replacement device market by product type



Notes :
 TMVI : Transcatheter mitral valve implantation
 TTVI : Transcatheter tricuspid valve implantation